АЛГОРИТМ ПРИМЕНЕНИЯ РЕКОМБИНАНТНОГО ФОЛЛИКУЛОСТИМУЛИРУЮЩЕГО ГОРМОНА В КЛИНИЧЕСКОЙ ПРАКТИКЕ

1. Cakmak H., Katz A., Cedars M.I., Rosen M.P. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013; 100: 1673-80. https://doi.org/10.1016/j.fertnstert.2013.07.1992.

2. von Wolff M., Thaler C.J., Frambach T., Zeeb C., Lawrenz B., Popovici R.M. et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009; 92: 1360-5, https://doi.org/10.1016/j.fertnstert.2008.08.011.

3. Kim J.H., Kim S.K., Lee H.J., Lee J.R., Jee B.C., Suh C.S. et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015; 30: 290-5. https://doi.org/10.3346/jkms.2015.30.3.290.

4. Kuang Y., Chen Q., Hong Q., Lyu Q., Ai A., Fu Y., Shoham Z. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai proto- col). Reprod Biomed Online. 2014; 29: 684-91. https://doi.org/10.1016/j.rbmo.2014.08.009.

5. Muteshi C., Child T., Ohuma E., Fatum M. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation — cohort study. Eur J Obstet Gynecol Reprod Biol. 2018; 230: 10-4. https://doi.Org/10.1016/j.ejogrb.2018.09.007.

6. Oliveira J.B.A., Mauri A.L., Petersen C.G. et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH- agonist protocol: a meta-analysis. J Ass Reprod Genet. 2007; 24(2-3): 67-75. https://doi.org/10.1007/s10815-006-9095-4.

7. Ягудина Р.И., Крылов В.А. Эволюция лекарственного сопровождения в протоколах контролируемой овариальной стимуляции. Современная организация лекарственного обеспечения. 2018; 2: 124.

8. Крылов В.А., Ягудина Р.И. Актуальность проведения клинико-экономической оценки лекарственных средств, применяемых в экстракорпоральном оплодотворении (ЭКО) в российской федерации. Фармакоэкономика: теория и практика. 2018; 6(1): 55.

9. Baruffi R., Mauri A.L., Petersen C. et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a metaanalysis. Reprod Biomed Online. 2007; 14(1): 14-25. https://doi.org/10.1016/s1472-6483(10)60758-4.

10. Kolibianakis E.M., Kalogeropoulou L., Griesinger G. et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update. 2007; 13(5): 445-52. https://doi.org/10.1093/humupd/dmm008.

11. Perin P.M., Maluf M., Czeresnia C.E. et al. The effect of recombinant human luteinizing hormone on oocyte/embryo quality and treatment outcome in down- regulated women undergoing in vitro fertilization. Fertil Steril. 2003; 80: Suppl 3: S76-S77. https://doi.org/10.1016/S0015-0282(03)02005-3.

12. Zhao Z., Shi H., Li J. et al. Cumulative live birth rates according to the number of oocytes retrieved following the “freeze-all” strategy. Reprod Biol Endocrinol. 2020; 18: 14. https://doi.org/10.1186/s12958-020-00574-3..

13. Al-Inany H.G., Youssef M.A., Ayeleke R.O., Brown J., Lam W.S., Broekmans F.J. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane database Syst Rev. 2016; 4(4): CD001750. https://doi.org/10.1002/14651858.CD001750.pub4.

14. Lambalk C.B., Banga F.R., Huirne J.A., Toftager M., Pinborg A., Homburg R. et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and metaanalysis accounting for patient type. Hum Reprod Update. 2017; 23(5): 560-79. https://doi.org/10.1093/humupd/dmx017.

15. Wang R., Lin S., Wang Y., Qian W., Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysis. PLoS One. 2017; 12(4): e0175985. https://doi.org/10.1371/journal.pone.0175985.

16. van Wely M., Kwan I., Burt A.L., Thomas J., Vail A., Van der Veen F., Al-Inany H.G. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011; 2011(2): CD005354. https://doi.org/10.1002/14651858.CD005354.pub2.

17. O’Flynn N. Assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract. 2014; 64(618): 50-1. https://doi.org/10.3399/ bjgp14X676609.

18. Qiao J., Zhang Y., Liang X., Ho T., Huang H.-Y., Kim S.-H., Goethberg M., Mannaerts B., Arce J.-C., on behalf of the Asian Follitropin Delta Phase 3 Trial (GRAPE) Group. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction. June 2021. https://doi.org/10.1093/humrep/deab155.

19. Chen L., Chen C., Kong X., Qiu C. Effects of luteinizing hormone supplementation on ovarian response and assisted reproductive technology outcomes in antagonist in vitro fertilization/intracytoplasmic sperm injection cycles: a meta-analysis. Reprod Dev Med. 2019: 3(2): 88-98. https://doi.org/10.4103/2096-2924.262386

20. Youssef M.A.-F., van Wely M., Mochtar M., Fouda U.M., Eldaly A., El Abidin E.Z. et al. Low dosing of gonadotropins in in vitro fertilization cycles for women with poor ovarian reserve: systematic review and meta-analysis. Fertil Steril. 2018; 109(2): 289-301. https://doi.org/10.1016/j.fertnstert.2017.10.033.

21. Baker V.L., Brown M.B., Luke B., Smith G.W., Ireland J.J. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. Fertil Steril. 2015; 104(5): 1145-52. e1-5. https://doi.org/10.1016/j.fertnstert.2015.07.1151.

22. Elonva/ European Medicines Agency